Recent news on Trospium

Alkermes and Indevus Announce Initiation of Phase 2a Clinical ...  -  Apr 25, 2007
PipelineReview.com (press release),ALKS 27 is an inhaled formulation of trospium chloride based on Alkermes’ proprietary AIR(R) pulmonary technology. CAMBRIDGE, MA and LEXINGTON, MA,

Alkermes and Indevus Initiates Phase 2a Clinical Study of ALKS 27  -  26 Apr 2007
ADMET.net (press release),ALKS 27 is an inhaled formulation of trospium chloride based on Alkermes' proprietary AIR® pulmonary technology. The study will assess the safety,

Indevus Pharmaceuticals Announces First Quarter Fiscal 2007 ...  -  Feb 7, 2007
Earthtimes.orgIn January, the Company announced its joint collaboration agreement with Alkermes, Inc., for the development of ALKS 27, an inhaled formulation of trospium

Alkermes and Indevus Announce Joint Collaboration to Develop ...  -  Jan 5, 2007
PipelineReview.com (press release),...“ALKS 27 combines our proprietary AIR technology with Indevus’ trospium chloride, a molecule with a known safety profile and proven efficacy in certain

Market Report -- In Play (ALKS)  -  Jan 4, 2007
MSN MoneyAlkermes and Indevus announce joint collaboration to develop inhaled formulation of Trospium Chloride for the treatment of COPD Alkermes and Indevus

Indevus Pharmaceuticals Is Pulling Back After The Bell  -  Jan 4, 2007
Trading Markets,PowerRating) for the development of ALKS 27, an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease.

FDA Accepts New Drug Application For SANCTURA XR(TM) Submitted By ...  -  Dec 25, 2006
Medical News Today (press release),Indevus licensed trospium chloride from Madaus GmbH, which markets the product for overactive bladder in multiple countries outside the United States.

Biotech Stocks Day-in-Review: BioCryst Gets Flu Drug Support  -  Jan 5, 2007
Seeking Alpha,The Indevus drug, marketed as Sanctura for overactive bladder, is trospium chloride, a muscarinic receptor antagonist that relaxes smooth muscle tissue.

FDA Accepts New Drug Application For SANCTURA XR(TM) Submitted By ...  -  Dec 25, 2006
Medical News Today (press release),Indevus licensed trospium chloride from Madaus GmbH, which markets the product for overactive bladder in multiple countries outside the United States.

FDA Accepts New Drug Application for SANCTURA XR(TM) Submitted by ...  -  Dec 14, 2006
PipelineReview.com (press release),Today announced that the US Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application (NDA) for SANCTURA XR (trospium

Indevus Pharmaceuticals Posted Modest Gains On SANTURA XR News  -  Dec 13, 2006
Trading Markets,...and Drug Administration has accepted for review its New Drug Application for SANCTURA XR or trospium choloride for the treatment of overactive bladder.

Indevus Announces Licensing and Manufacturing Pact for SANCTURA XR ...  Nov 6, 2006
...(Nasdaq: IDEV) today announced that it has licensed the rights to sell SANCTURA XR, the once-daily formulation of trospium chloride, in certain territories ... -PR Newswire (press release), Indevus Announces Licensing and Manufacturing Pact for Sanctura XR ...  Nov 6, 2006
...today announced that it has licensed the rights to sell SANCTURA XR, the once-daily formulation of trospium chloride, in certain territories outside the US, to ... -PharmaLive.com (press release), Indevus enters licensing pact with Madaus  Nov 7, 2006
Indevus Pharmaceuticals has licensed the rights to sell Sanctura XR, the once-daily formulation of trospium chloride for overactive bladder to Madaus, in ... -Pharmaceutical Business Review Indevus Announces Licensing and Manufacturing Pact for SANCTURA XR ...  Nov 6, 2006
..."This agreement increases the economic opportunity for Indevus as Madaus currently markets trospium chloride through much of the world either directly or ... -Earthtimes.org Market Report -- In Play (WIRES)  Nov 6, 2006
Indevus Pharmaceuticals (IDEV) announced that it has licensed the rights to sell SANCTURA XR, the once-daily formulation of trospium chloride, in certain ... -MSN Money Indevus Announces Submission of New Drug Application Seeking ...  Oct 12, 2006
SANCTURA XR is the once-daily formulation of SANCTURA® (trospium chloride), which is currently marketed for overactive bladder. ... -Yahoo! News (press release) Indevus Announces Submission of New Drug Application Seeking ...  Oct 12, 2006
Indevus licensed trospium chloride from Madaus GmbH, which markets the product for overactive bladder in multiple countries outside the United States. ... -Earthtimes.org Part D coverage gap looms large  Sep 11, 2006
...found none of the five drugs oxybutynin (Ditroplan, Ditroplan XL and Oxytrol, a skin patch), tolterodine (Detrol, Detrol LA), trospium (Sanctura), solifenacin ... -Syracuse Post Standard

Health Highlights: Sept. 6, 2006  Sep 6, 2006
...taking any of the five drugs -- oxybutynin (Ditropan, Ditropan XL and Oxytrol, a skin patch); tolterodine (Detrol, Detrol LA); trospium (Sanctura); solifenacin ... -Forbes



Depomed and Madaus Srl Announce Acceptance of the Application for ...  Mar 29, 2006
...countries. Madaus has a varied product portfolio targeting urology, including proprietary products such as Trospium Chloride. Urology ... - Genetic Engineering News

Treating an Overactive Bladder  Apr 2, 2006
Among the more commonly used are tolterodine and oxybutynin. Other drugs that can be used are trospium chloride, darifenacin and solifenacin. ... - International News Service

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional